R E S U M O

I N T R O D U C T I O N
The beneficial effects of soy protein on serum lipids have been extensively studied in the last decades [1] [2] [3] [4] . The classic Anderson et al. 1 metaanalysis showed that an average daily intake of 47g of soy protein was associated with a 9.3% reduction in total serum cholesterol, 12.9% reduction in Low Density Lipoprotein-cholesterol (LDL-c), and 10.5 % reduction in triacylglycerols. According to the IV Diretriz Brasileira sobre Dislipidemia e Prevenção de Aterosclerose, a daily intake of 25 grams of soy reduces plasma cholesterol (LDL-c) by 6% 5 . However, the optimal soy and isoflavones intake has also been debated. Anderson et al. 1 reported that an intake of 47g/d of soy protein has a beneficial effect, but the authors did not specify how much isoflavones were consumed. Zhuo et al. 3 suggested an average intake of 50g/d of soy protein with high isoflavone concentration (96mg/d). Weggemans & Trautwein 2 did not find a dose-response relationship between soy-associated isoflavones and changes in LDL or High Density Lipoprotein-cholesterol (HDL-c). Zhan & Ho 4 suggested that a daily intake of 80mg or more of isoflavones has a better effect on the lipid profile.
In 1999, the US Food and Drug Administration (FDA) recommended an intake of at least 25g of soy protein daily as part of a low fat diet, which in turn, may reduce the risk of heart disease 6 . In 2007, the FDA announced its intent to reevaluate the scientific evidence for soy protein intake and the risk of coronary heart disease using its newly proposed evidence-based guideline 7 
.
Many questions remain unanswered. There is a lack of consistency on whether the changes in lipid profile are due mainly to isoflavones and what amount of soy protein containing isoflavones is most beneficial. Another problem is that most trials pool together men and women in their analyses. A recent meta-analysis 4 showed that total cholesterol and LDL-c were greater reduced in men than in women, suggesting that the effect of soy protein may vary according to gender. In addition, a review on soy protein, isoflavones and cardiovascular health showed that, although soy protein, as compared with others proteins, mainly milk protein, may have an effect on LDL-c, its effect on other CVD risk factors has not been confirmed by studies done in the last 10 years 8 . Furthermore, the quality of the studies included in the previous metaanalysis has not been assessed.
The main objective of this meta-analysis was to investigate the effect of soy protein containing isoflavones (ISP) on the serum concentrations of total cholesterol, LDL-c, triacylglycerol and HDL-c in adult women.
M E T H O D S
Identification and selection studies
The medical literature was systematically searched for randomized controlled trials published from 1966 to March 2005 on the effects of soy protein containing isoflavones on the serum lipids of women. The main searched databases were PubMed, Cochrane Library, Lilacs and Web of Science. The searched keywords were: "soy", "soy protein", "soybean proteins" "women", "female", "cholesterol", and "randomized controlled trial". The Grey Literature was also searched: System for Information on Grey Literature (SIGLE), National Technical Information Service (NTIS), Trials Central and Current Controlled Trials, but no relevant studies were found. The references of the selected studies were also examined. Language was not a selection criterion but only trials published in English met the inclusion criteria.
Randomized controlled trials were included if they met the following criteria: published from 1966 to March 2005, the study population consisted only of adult women, the design was either crossover or parallel and the amounts of soy protein and isoflavones consumed were provided.
Studies were excluded if there was no control group; if the amounts of soy protein and isoflavones, and the lipid concentrations, both at baseline and following the intervention were not provided; if other substances that could affect serum lipid levels were also given to participants; and if they included subjects with a history of chronic diseases that could affect lipid concentrations. A total of 15 studies were eligible according to the above criteria.
Three independent reviewers assessed the quality of the studies before inclusion in the metaanalysis. The following items were considered: took into account the generation of randomization sequence, allocation concealment, blinding, compliance with the intervention, and analysis by intention to treat 9 . Each trial was given a score from 0 to 10. Two articles were excluded during this phase because their scores were very low; thus, 13 articles were selected for the meta-analysis.
Data extraction and analysis
The meta-analysis was conducted using Revman 4.2.7 and Stata 7 software. The outcome variables considered for the analysis were total cholesterol, LDL-c, HDL-c and triacylglycerol recorded as continuous variables.
The estimate of effect was defined as the mean difference (net change in mg/dL) between the change in lipid concentrations in subjects consuming soy protein with isoflavones (final value minus initial value) and in subjects consuming the control diet.
In studies with more than one treatment group (soy protein) the effect of all groups were compared with the control group, except those groups with very low soy concentration (ISP-≤4.4mg), which were excluded from the analysis ( Table 1) . This was because such low concentrations were similar to those given to subjects in some control groups.
For the computation of pooled effects, we used the weighted mean difference and each study was assigned a weight consisting of the reciprocal of its variance. Fixed-effects models were used for the main results because no heterogeneity (p≥0.05) or inconsistencies (I 2 =0) among the studies were detected. Randomeffects models were used in subgroup analyses that showed some level of heterogeneity or inconsistency.
To explore the possible influence of covariates on the net change in lipid concentrations, subgroup analyses were also done according to initial lipid concentrations, menopausal status, study design (parallel or crossover), concentration of isoflavones (≤40mg; 41.1 to 79.9mg; ≥80mg), length of follow-up (6 to 8wk; 12wk; 24 to 60wk), and type of diet (usual or low fat diet).
Finally, to examine potential publication bias, Standard Errors (SE) of the study effects were plotted against their corresponding effect sizes and Begg's and Egger's tests were performed. Table I shows selected characteristics of the 13 studies that met the eligibility criteria, yielding 18 comparisons. Overall, 772 women were included in the meta-analysis. The size of the studies varied from 13 to 175 subjects per study. The mean age of the women was 54.6 years (18 to 75 year-olds). Most studies included postmenopausal women [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In six studies, women were hypercholesterolemic at baseline [10] [11] [12] [13] 15, 18 . Seven studies used a parallel randomized design 10, [13] [14] [15] [16] 18, 20 and six used a crossover design 11, 12, 17, 19, 21, 22 . All studies used isolated soy protein containing isoflavones and the median soy protein intake was 40g/day (20 to 63g/day). The median isoflavone concentration was 80mg (2 to 132mg/day). Trials varied in length from 6 to 60 weeks, with a median duration of 12 weeks. Control groups received casein 10, 12, 13, 18 , milk protein 11, 15, 16 , whey protein 20 , complex carbohydrates 22 , and ISP with traces of or no isoflavone content 14, 17, 19, 21 . In two studies all participants were instructed to follow a National Cholesterol Education Program (NCEP) step I diet during the study (<30% dietary energy as total fat, <10% energy as saturated fat and <300mg/day of cholesterol) 10, 12 . Table 1 . Characteristics of the 13 studies and 18 comparisons included in the meta-analysis.
R E S U L T S Characteristics of the studies
Baum et al. 10 Baum et al. 10 Blum et al. 11 Cuevas et al. 12 Dalais et al. 13 Dent et al. 20 Dent et al. 20 Gallagher et al. 14 Gallagher et al. 14 Gardner et al. 15 Gardner et al. 15 Kreijkamp-Kaspers et al. 16 Merz-Demlow et al. 21 Merz-Demlow et al. 21 Steinberg et al. 17 Steinberg et al. 17 Vigna et al. 18 Wangen et al. 19 Wangen et al. 19 Whashburn et al. 22 Whashburn et al. k NCEP SI -National Cholesterol Education Program (NCEP) step I diet (<30% dietary energy from total fat, <10% energy from saturated fat and <300mg/day of cholesterol).
Quality assessment
All papers reported a randomized design, but only 2 studies described the random sequence generation and the adopted allocation concealment 15, 16 . With regard to blinding, all studies reported double-blinding, but only 6 provided a further description of the blinding procedures or the nature of the placebo 11, [13] [14] [15] [16] 20 . In most of the articles, losses to follow-up were stated or deducible from tables. Only 1 study used intention-to-treat analysis 16 . The mean quality score was 6.3.
Changes in serum lipid concentrations
A statistically significant effect of soy protein containing isoflavones was observed only in the outcome total cholesterol (Figure 1 ). Total cholesterol decreased in the soy protein group compared with the corresponding control group in 13 (72%) of the 18 comparisons. The pooled estimate of the effects of the intervention on total cholesterol was a decrease of 5.34mg/dL (95% CI= -10.30 to -0.38; p=0.03), or 2.4%.
Soy protein intake did not affect serum LDL-c, HDL-c and triacylglycerol levels significantly. LDL-c decreased in the group consuming soy protein containing isoflavones compared with the corresponding control group in 13 (81%) of the 16 comparisons in which LDL-c was measured (Figure 2 Figure 3 ).
Subgroup analysis
In the subgroup analyses, the pooled estimates of soy protein effect on total cholesterol was significant when soy protein intake exceeded 40g (p=0.04), in crossover-design studies (p=0.05), and in those in which the subjects were on their usual diets (p=0.05); the significance was borderline in studies with the shortest intervention time (6 to 8wk) (p=0.07), and those including both normal and hypercholesterolemic subjects (p=0.08) ( Table 2 ). With regard to other outcomes, there were no significant results except for borderline significance regarding LDL-c in the subgroup consuming ≥40g of soy protein (mean change=-5.02mg/dL; 95% CI: -11.20 to 0.77; p=0.09). Although not statistically significant, a gradient was observed in relation to the isoflavone concentration used in the treatment groups. The effect was stronger in groups consuming higher concentrations (≥80mg de isoflavones). 
Publication bias
The Egger's test showed significant results for total cholesterol and HDL-cholesterol (P=0.033 and P= 0.013, respectively) and Begg's test was not significant for any of the outcomes. The funnel plots did not show any asymmetry.
D I S C U S S I O N
The present meta-analysis investigated the effect of soy protein containing isoflavones on the serum lipid levels of women. The results showed that there was a significant decrease (-5.34mg/dL) in total serum cholesterol following diet supplementation with soy protein. Similar, but greater effects were reported by Anderson et al. meta-analysis contained subjects with much higher baseline serum cholesterol levels and their interventions contained larger amounts of soy protein. In addition, these meta-analyses pooled together men and women in their analyses. Our study population included only women, and several studies included normocholesterolemic women. In fact, the effect size of our study was similar to those reported by Zhan & Ho 4 for women, in a sub-group analysis according to gender. The authors also reported greater reductions of total cholesterol in men, suggesting that gender may have a modifying effect, with possibly smaller effects among women (-6.18mg/dL). No significant associations were reported elsewhere 2, 3 .
No statistically significant effects were found for LDL-c, HDL-c and triacylglycerol by the present study. However, this may be due to type-II error. It may be due to the relatively small number of studies, and therefore total size, resulting in a reduced power of detecting significant effects of the intervention. To some extent, the effect size found in the present study is similar to that reported by Zhan & Ho 4 . The net change in our result was -3.50mg/dL for LDL-c, -8.86mg/dL for triacylglycerol and 0.91mg/dL for HDL-c; whereas Zhan and Ho 4 reported -5.40mg/ dL, -5.31 mg/dL and 0.77mg/dL, respectively. That is, the present meta-analysis was consistent with previously reported results for women.
The soy components responsible for the beneficial effects on the cholesterol levels and their mechanisms of action on the lipid profile are still being investigated. Most studies support the 'isoflavone hypothesis 23, 24 . Isoflavones are structurally similar to estrogen and bind to its receptors, promoting a weaker estrogenic response, with beneficial effects on lipid metabolism 25 . The literature seems to confirm this beneficial effect 1, 4 . Although the results were not significant, the present study found that apparently there is a biological gradient in studies with higher concentrations of isoflavones (≥80mg) in the treatment groups that experienced greater cholesterol reduction (-8.88 mg/dL; IC 95%: -23.55 to 5.4) ( Table 2 ). Several studies have reported a greater reduction in blood lipids when soy protein was combined with isoflavones (compared with absence of isoflavones) 10, 15, 19, 21, 26 . However, some studies assessed the lipid-lowering effect of isolated isoflavones (without its protein component) on postmenopausal women and found no differences 27, 28 . unaccounted shifts in the fatty acid, cholesterol, or fiber content of diets used in earlier studies 35 .
Many studies have demonstrated that the reduction in lipid and lipoprotein levels in many people is small, but soy protein consumption produces significant changes overall 36 . These differences are relatively small when taken quantitatively, but they are reported in most studies. They are probably due to many possibilities that go from the chemical quality of the soy protein to the differences of its effect secondary to metabolic complexity and human genetics.
Subgroup analyses showed borderline effects of shorter intervention periods (6 to 8 weeks) on the outcome total cholesterol. A similar result was found by Allen et al. 37 . They found that total cholesterol reduced significantly after consuming soy protein with isoflavones for 6 weeks but no further statistically significant reduction was found after 12 weeks. This could also result from diet fatigue, that is, lower product adherence in longer interventions 4 .
Longer interventions were not effective, which raises the possibility of reduced compliance. Only 6 studies analyzed compliance to the intervention by determining urine or serum isoflavone levels 13, 14, 16, 17, 19, 20 . In other studies, compliance relied on participant's reports or on the number of packages returned but both methods are considered inappropriate 9 .
Fixed-effects models were used for the main results because no heterogeneity or inconsistencies were detected. But in some of the sub-group analyses, the assumption of heterogeneity implied the use of random-effects models. Heterogeneity in these cases can probably be attributed to differences in soy protein and isoflavone intake, study duration and baseline lipid levels across studies.
The present study found some evidence for publication bias when evaluating the outcomes total cholesterol and HDL-cholesterol. However, publication bias is not the only explanation for asymmetrical funnel plots or It is important to remember that soy intake may be affected by an individual's ability to produce equol (a component produced by humans after soy intake). Equol is an isoflavone metabolite that presents greater affinity for the estrogen receptor than its precursor daidzein. Therefore, metabolic variability needs to be considered: individuals who produce less equol benefit less 27 .
In spite of the apparent dose-response relationship, consistency and biological plausibility, which strengthen the hypothesis of a causal relationship between isoflavones and reduction of total cholesterol, the presence of other soy components cannot be ignored, and they have not been analyzed in most studies. The significant association between the total amount of soy protein consumed and total cholesterol reduction (p=0.04) may also be related to other soy protein components.
Most of the beneficial effects are attributed to isoflavones, natural selective estrogen receptor modulators, whose effects on lipoproteins are similar to those of estrogen, namely decreasing LDL-c and increasing HDL-c 29, 30 . Nevertheless, soy protein contains other components, such as storage peptides 31 , saponins and fiber 32 . These components have been linked with a decrease in serum lipids, yet they have not been quantified or taken into account by most studies. For example, specific peptides and saponins can affect blood cholesterol levels. Specific peptides from soy proteins can modulate cholesterol homeostasis, eliciting a cholesterollowering effect 31 . In addition, saponins may play a role in mediating the hypercholesterolemic activity of soy protein 33, 34 . One of the possible mechanisms by which saponins and fiber can affect cholesterol metabolism is by forming mixed micelles that can interfere in the enterohepatic circulation of bile acids, blocking the reabsorption of bile acids from the terminal ileum 32 .
Discrepancy among findings may be due to the presence or absence of specific components associated with soy protein preparations or significant test results. Other possibilities include true heterogeneity, variation in the methodological quality of the studies, analysis of small studies, confounding heterogeneity due to poor choice of effect measure, and chance. Furthermore, since the present meta-analysis included few studies, care should be exercised when interpreting nonsignificant results for publication bias tests. Publication bias may exist even with nonsignificant results 38, 39 .
The present study also used more stringent selection criteria leading to improved metaanalysis quality. In addition, each selected study in this meta-analysis had its quality evaluated, something not reported in other meta-analyses. Interpretation of the findings of a study depends on design, conduct and analyses (internal validity), as well as on populations, interventions and outcome measures (external validity) 40 . In the present meta-analysis, only a couple of studies detailed the randomization process. Absence of randomization can distort effects in either direction and it is impossible to predict whether bias has been avoided in any particular nonrandomized study 41, 42 . Moreover, blinding makes it difficult to bias results intentionally or unintentionally, and so helps to ensure conclusion credibility 43, 44 . Less than 50% of the studies eligible for the present meta-analysis provided further description of the blinding procedures or on the nature of the placebo and the average score was relatively low.
Although the present meta-analysis found a statistically significant reduction in total serum cholesterol due to consumption of soy protein containing isoflavones, this reduction was clinically insignificant. A meta-analysis of 38 large clinical trials including primary and secondary preventions found total cholesterol needs to be reduced by 10% for the risk of mortality from cardiovascular disease to reduce by 15% and the risk of total mortality to reduce by 11% 45 . The present metaanalysis showed that total cholesterol decreased by only 2.4%.
C O N C L U S I O N
In summary, these findings suggest small statistically significant effects on the total serum cholesterol of women, but they are clinically insignificant. Furthermore, there were no statistically significant effects on serum LDL-c, HDL-c or triglycerides.
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